ATE519493T1 - Blockierendes peptid für die sekretion von entzündungszellen - Google Patents

Blockierendes peptid für die sekretion von entzündungszellen

Info

Publication number
ATE519493T1
ATE519493T1 AT02756467T AT02756467T ATE519493T1 AT E519493 T1 ATE519493 T1 AT E519493T1 AT 02756467 T AT02756467 T AT 02756467T AT 02756467 T AT02756467 T AT 02756467T AT E519493 T1 ATE519493 T1 AT E519493T1
Authority
AT
Austria
Prior art keywords
secretion
present
inflammatory cell
cell secretion
blocking peptide
Prior art date
Application number
AT02756467T
Other languages
English (en)
Inventor
Linda Martin
Kenneth Adler
Yuehua Li
Original Assignee
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State filed Critical Univ North Carolina State
Application granted granted Critical
Publication of ATE519493T1 publication Critical patent/ATE519493T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02756467T 2001-06-26 2002-06-26 Blockierendes peptid für die sekretion von entzündungszellen ATE519493T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30093301P 2001-06-26 2001-06-26
PCT/US2002/022270 WO2003000027A2 (en) 2001-06-26 2002-06-26 Blocking peptide for inflammatory cell secretion

Publications (1)

Publication Number Publication Date
ATE519493T1 true ATE519493T1 (de) 2011-08-15

Family

ID=23161217

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02756467T ATE519493T1 (de) 2001-06-26 2002-06-26 Blockierendes peptid für die sekretion von entzündungszellen

Country Status (11)

Country Link
US (2) US20030013652A1 (de)
EP (1) EP1411967B1 (de)
JP (1) JP4610891B2 (de)
AT (1) ATE519493T1 (de)
AU (1) AU2002322475B2 (de)
CA (1) CA2452123A1 (de)
DK (1) DK1411967T3 (de)
ES (1) ES2369760T3 (de)
HK (1) HK1065702A1 (de)
PT (1) PT1411967E (de)
WO (1) WO2003000027A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544772B2 (en) * 2001-06-26 2009-06-09 Biomarck Pharmaceuticals, Ltd. Methods for regulating inflammatory mediators and peptides useful therein
US8501911B2 (en) 1999-02-24 2013-08-06 Biomarck Pharmaceuticals, Ltd Methods of reducing inflammation and mucus hypersecretion
NZ560412A (en) * 2005-01-20 2009-06-26 Biomarck Pharmaceuticals Ltd Mucin hypersecretion inhibitors based on the structure of MANS and methods of use
EP1948238B1 (de) 2005-11-10 2013-08-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Zusammensetzungen und Verfahren zur Behandlung von Sucht und anderen neuropsychiatrischen Erkrankungen
ES2725599T3 (es) * 2006-07-26 2019-09-25 Biomarck Pharmaceuticals Ltd Métodos para atenuar la liberación de mediadores inflamatorios y péptidos útiles en los mismos
RU2674259C2 (ru) 2010-06-16 2018-12-06 Эмбера Ньюротерапьютикс, Инк Композиции и способы лечения зависимости, психических расстройств и нейродегенеративного заболевания
DK2981279T3 (en) 2013-04-05 2019-03-25 Biomarck Pharmaceuticals Ltd MARCKS INHIBITOR PERIODS FOR INHIBITING METASTASES
ES2952744T3 (es) 2016-12-15 2023-11-03 Nestle Sa Composiciones y procedimientos que modulan los glóbulos blancos o los neutrófilos en un animal de compañía
BR112019018700A2 (pt) 2017-03-10 2020-04-07 Embera Neurotherapeutics Inc composições farmacêuticas e seus usos
AU2020298130A1 (en) * 2019-06-17 2022-01-20 Biomarck Pharmaceuticals Ltd. Peptides and methods of use thereof in treating uveitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
CA2102142A1 (en) * 1993-03-30 1994-10-01 Andrew J. Ghio Method of inhibiting oxidants using alkylaryl polyether alcohol polymers
EP1538162B1 (de) * 1999-02-24 2012-04-11 North Carolina State University Verbindungen zur Veränderung der Schleimsekretion
US6506779B1 (en) * 1999-12-03 2003-01-14 Pfizer Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
ITTO20030856A1 (it) * 2003-10-31 2005-05-01 Skf Ab Attuatore lineare a vite a ricircolo di sfere con un dispositivo di sbloccaggio di sicurezza.

Also Published As

Publication number Publication date
EP1411967B1 (de) 2011-08-10
US20030013652A1 (en) 2003-01-16
WO2003000027A3 (en) 2003-05-08
ES2369760T3 (es) 2011-12-05
EP1411967A2 (de) 2004-04-28
EP1411967A4 (de) 2004-12-15
JP2005519850A (ja) 2005-07-07
JP4610891B2 (ja) 2011-01-12
HK1065702A1 (en) 2005-03-04
PT1411967E (pt) 2011-09-30
WO2003000027A2 (en) 2003-01-03
AU2002322475B2 (en) 2008-02-21
DK1411967T3 (da) 2011-11-28
US20040180836A1 (en) 2004-09-16
CA2452123A1 (en) 2003-03-01

Similar Documents

Publication Publication Date Title
MXPA02004666A (es) Gelatinas recombinantes.
ATE519493T1 (de) Blockierendes peptid für die sekretion von entzündungszellen
DK1015622T3 (da) Praktisk sialylering in vitro af rekombinante glycoproteiner
ATE469911T1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
IL162648A0 (en) Cellular compositions and methods of making and using them
DE69936351D1 (de) Glykosylierte proteine mit reduzierter allergenität
ATE541857T1 (de) Optimierte fc-varianten und herstellungsverfahren dafür
DE50109164D1 (de) Therapeutische verwendung von extrakten aus sophora flavescens oder sophora subprostrata
WO2007075438A3 (en) Polypeptides comprising unnatural amino acids, methods for their production and uses therefor
DE502005009449D1 (de) Metallreflektor und Verfahren zu dessen Herstellung
EP1401869A4 (de) Moleküle und verfahren zur inhibierung der freisetzung von kim-1
MXPA04002562A (es) Combinacion de un pde-4 y nsaid.
PL355993A1 (en) Selective electrochemical reduction of halogenated 4-aminopicolinic acids
NO20044898L (no) Nye etonogestrel estere
MX2009000975A (es) Metodos para atenuar la liberacion de mediadores inflamatorios y peptidos utiles en ellos.
BR0016632A (pt) Métodos e composições para a fabricação de lentes oftálmicas
TW200715814A (en) Mobile communication device with silent conversation capability
NO20040604L (no) Trisykliske imidazolpyridiner
DE60209359D1 (de) Lösungsmittelverklebungsverfahren
HUP0402165A2 (hu) Nem neurotoxikus plazminogén aktiváló faktorok a szélhűdés kezelésére
DE60214676D1 (de) Hochaffine antagonisten der elr-cxc chemokine
TW200741132A (en) Luminescent element
ATE468698T1 (de) Trägeraufbau für einen multimedia-dienst
IL158278A0 (en) Chitosan and hydroxy carboxylic acid based porous and non-porous matrices
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1411967

Country of ref document: EP